Opinion

Video

Final Thoughts and Clinical Trials in NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Please share your concluding thoughts about the recent progress and future outlook of NMIBC.
      Related Videos
      An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
      An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
      1 expert is featured in this series.
      Case 2: A 63-Year-Old Man With Recurrent HSPC
      1 expert is featured in this series.
      Comorbidities and Adherence: Tailoring mHSPC Treatment
      FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
      FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      2 experts are featured in this series.
      Treatment or Lack of Treatment of Small Renal Masses
      1 expert is featured in this series.
      The current treatment landscape of mHSPC
      2 experts are featured in this series.
      Strengths and Weaknesses of Imaging Modalities in ccRCC
      1 expert in this video
      BPH: Strategies for Guiding Patients From Medication to Intervention
      1 expert is featured in this series.
      Representation of Black men with mHSPC in clinical trials
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.